QT Variability Pre and Post Cardioversion (DCCV)

This study has been completed.
Sponsor:
Collaborators:
Wake Forest School of Medicine
Information provided by (Responsible Party):
Dawood Darbar, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00885391
First received: April 20, 2009
Last updated: December 16, 2013
Last verified: December 2013

April 20, 2009
December 16, 2013
January 2007
March 2012   (final data collection date for primary outcome measure)
QT variability before and after direct current cardioversion [ Time Frame: 1.5 ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00885391 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
QT Variability Pre and Post Cardioversion
QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation

The purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.

Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. These are interrelated responses and the extent to which these or other pathophysiologic responses determine QT interval during and after Atrial Fibrillation (AF) is unknown. In this study, the QT variability is related to those potential markers in patients with AF undergoing elective DC-cardioversion.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Cardiology Clinic Hospital inpatient

Atrial Fibrillation
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
219
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • At least 21 years of age
  • Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center

Exclusion Criteria:

  • Undergoing emergent DC-Cardioversion of atrial fibrillation for hemodynamic instability
  • Undergoing DC-Cardioversion for post-cardiac surgery
  • Dual chamber pacemakers
Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00885391
060908, RO1-HL085690-01A2
No
Dawood Darbar, Vanderbilt University
Vanderbilt University
  • National Institutes of Health (NIH)
  • Wake Forest School of Medicine
Principal Investigator: Dawood Darbar, M.D., Ph.D., F.A.C.C. Vanderbilt University
Vanderbilt University
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP